Cargando…
A retrospective cohort study on the efficacy and safety for combination therapy of immunotherapy, targeted agent, and chemotherapy versus immunochemotherapy or chemotherapy alone in the first-line treatment of advanced biliary tract carcinoma
BACKGROUND: A paucity of effective treatment for biliary tract carcinoma (BTC) has necessitated the investigation into new therapies. As combinations of targeted therapy with immunotherapy are well-established in hepatocellular carcinoma, the GEMOX chemotherapy (gemcitabine and oxaliplatin) is the s...
Autores principales: | Zeng, Jie, Ma, Jie, Zeng, Zhiming, Yang, Lihua, Jiang, Yanfeng, Mo, Ning, Ma, Fuchao, Liu, Cuizhen, Li, Rong, Tang, Jing, Qin, Shanyu, Jiang, Haixing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186497/ https://www.ncbi.nlm.nih.gov/pubmed/37201053 http://dx.doi.org/10.21037/jgo-23-218 |
Ejemplares similares
-
Efficacy and Safety of First-Line Chemotherapies for Patients With Advanced Biliary Tract Carcinoma: A Systematic Review and Network Meta-Analysis
por: Jiang, Yanfeng, et al.
Publicado: (2021) -
Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion
por: Nio, Y, et al.
Publicado: (1999) -
Immunochemotherapy or chemotherapy alone in primary central nervous system lymphoma: a National Cancer Database analysis
por: Ollila, Thomas A., et al.
Publicado: (2023) -
Efficacy and safety analysis of chemotherapy combined with immunotherapy compared with standard chemotherapy for advanced biliary tract malignant tumors
por: Zhang, Zhengfeng, et al.
Publicado: (2023) -
Chemotherapy for Biliary Tract Cancer in 2021
por: Sasaki, Takashi, et al.
Publicado: (2021)